Stratification of resectable lung adenocarcinoma by molecular and pathological risk estimators

European Journal of Cancer

Volumn 51, Issue 14, 2015, Pages 1897-1903

  Rakha, Emad ^a,b   Pajares, Maria J ^c   Ilie, Marius ^d   Pio, Ruben ^c   Echeveste, Jose ^e   Hughes, Elisha ^f   Soomro, Irshad ^b   Long, Elodie ^d   Idoate, Miguel A ^e   Wagner, Susanne ^f   Lanchbury, Jerry S ^f   Baldwin, David R ^b   Hofman, Paul ^d   Montuenga, Luis M ^c  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

^c UNIVERSITY OF NAVARRA   (Spain)

^d UNIVERSITY HOSPITAL OF NICE   (France)

^e UNIVERSITY CLINIC OF NAVARRA   (Spain)

^f Utah   (United States)

Author keywords

Expression signature; Lung adenocarcinoma; Post surgical treatment; Prognostic marker

Indexed keywords

CELL CYCLE PROTEIN; TUMOR MARKER;

ARTICLE; CANCER MORTALITY; CANCER PATIENT; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SIZE; CANCER STAGING; CELL CYCLE PROGRESSION; DISEASE SPECIFIC SURVIVAL; FEMALE; HIGH RISK PATIENT; HIGH RISK POPULATION; HUMAN; LOW RISK POPULATION; LUNG ADENOCARCINOMA; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; POSTOPERATIVE CARE; PRIMARY TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; RISK ASSESSMENT; SMOKING; TUMOR INVASION; ADENOCARCINOMA; CLINICAL TRIAL; DECISION SUPPORT SYSTEM; EUROPE; GENE EXPRESSION PROFILING; GENETICS; KAPLAN MEIER METHOD; LUNG NEOPLASMS; LUNG RESECTION; MORTALITY; MULTICENTER STUDY; PATHOLOGY; PREDICTIVE VALUE; PROCEDURES; PROPORTIONAL HAZARDS MODEL; REPRODUCIBILITY; RETROSPECTIVE STUDY; RISK FACTOR; VALIDATION STUDY;

ADENOCARCINOMA; CELL CYCLE PROTEINS; DECISION SUPPORT TECHNIQUES; EUROPE; FEMALE; GENE EXPRESSION PROFILING; HUMANS; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; NEOPLASM STAGING; PNEUMONECTOMY; POLYMERASE CHAIN REACTION; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 84939569661     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2015.07.015     Document Type: Article

References (34)

1. A. Jemal, F. Bay, M.M. Center, J. Ferlay, E. Ward, and D. Forman Global cancer statistics CA Cancer J Clin 61 2011 69 90
2. R. Siegel, J. Ma, Z. Zou, and A. Jemal Cancer statistics 2014 CA Cancer J Clin 64 2014 9 29
3. B.D. Smith, G.L. Smith, A. Hurria, G.N. Hortobagyi, and T.A. Buchholz Future of cancer incidence in the United States: Burdens upon an aging, changing nation J Clin Oncol 27 17 2009 2758 2765
4. D.R. Aberle, A.M. Adams, C.D. Berg, W.C. Black, J.D. Clapp, R.M. Fagerstrom, and et al. Reduced lung cancer mortality with low-dose computed tomographic screening N Engl J Med 365 2011 395 409
5. N. Horeweg, C.M. van der Aalst, E. Thunnissen, K. Nackaerts, C. Weenick, H.J.M. Groen, and et al. Characteristics of lung cancers detected by computer tomography screening in the randomized NELSON trial Am J Respir Crit Care Med 187 2013 848 854
6. R.P. Petersen, D. Pham, W.R. Burfeind, S.I. Hanish, E.M. Toloza, D.H. Harpole Jr., and et al. Thoracoscopic lobectomy facilitates the delivery of chemotherapy after resection for lung cancer Ann Thorac Surg 83 2007 1245 1249
7. B.A. Whitson, S.S. Groth, S.J. Duval, S.J. Swanson, and M.A. Maddaus Surgery for early-stage non-small cell lung cancer: a systematic review of the video-assisted thoracoscopic surgery versus thoracotomy approaches to lobectomy Ann Thorac Surg 86 2008 2008 2018
8. K. Chansky, J.P. Sculier, J.J. Crowley, D. Giroux, J. Van Meerbeeck, P. Goldstraw, and et al. The International Association for the Study of Lung Cancer Staging Project: prognostic factors and pathologic TNM stage in surgically managed non-small cell lung cancer J Thorac Oncol 4 2009 792 801
9. J.P. Pignon, H. Tribodet, G.V. Scagliotti, J.Y. Douillard, F.A. Shepherd, R.J. Stephens, and et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE collaborative group J Clin Oncol 26 2008 3552 3559
10. R. Arriagada, A. Dunant, J.P. Pignon, B. Bergman, M. Chabowski, D. Grunenwald, and et al. Long-term results of the international adjuvant lung cancer trial evaluation adjuvant cisplatin-based chemotherapy in resected lung cancer J Clin Oncol 28 2010 35 42
11. J.Y. Douillard, H. Tribodet, D. Aubert, F.A. Shepherd, R. Rosell, K. Ding, and et al. Adjuvant cisplatin and vinorelbine for completely resected non-small cell lung cancer: subgroup analysis of the lung adjuvant cisplatin evaluation J Thorac Oncol 5 2010 220 228
12. K.M. Pisters, W.K. Evans, C.G. Azzoli, M.G. Kris, C.A. Smith, C.E. Desch, and et al. Cancer Care Ontario and American Society of Clinical Oncology adjuvant chemotherapy and adjuvant radiation therapy for stages I-IIIA resectable non small-cell lung cancer guideline J Clin Oncol 25 2007 5506 5518
13. L. Crino, W. Weder, J. van Meerbeeck, E. Felip on behalf of the ESMO Guidelines Working Group Early stage and locally advanced (non-metastatic) non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Ann Oncol 21 2010 v103 v115
14. K. Shedden, J.M. Taylor, S.A. Enkemann, M.S. Tsao, T.J. Yeatman, W.L. Gerald, and et al. Gene expression-based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study Nat Med 14 2008 822 827
15. J. Subramanian, and R. Simon Gene expression-based prognostic signatures in lung cancer: ready for clinical use? J Natl Cancer Inst 102 2010 464 474
16. C.Q. Zhu, K. Ding, D. Strumpf, B.A. Weir, M. Meyerson, N. Pennell, and et al. Prognostic and predictive gene signature for adjuvant chemotherapy in resected non-small-cell lung cancer J Clin Oncol 28 2010 4417 4424
17. Y. Xie, G. Xiao, K. Coombes, C. Behrens, L.M. Solis, G. Raso, and et al. Robust gene expression signature from formalin-fixed paraffin-embedded samples predicts prognosis of non-small cell lung cancer patients Clin Cancer Res 17 2011 5705 5714
18. J.R. Kratz, J. He, S.K. Van Den Eeden, Z.H. Zhu, W. Gao, P.T. Pham, and et al. A practical molecular assay to predict survival in resected non-squamous, non-small-cell lung cancer: development and international validation studies Lancet 379 2012 823 832
19. H. Tang, G. Xiao, C. Behrens, J. Schiller, J. Allen, C.W. Chow, and et al. A 12-gene set predicts survival benefits from adjuvant chemotherapy in non-small cell lung cancer patients Clin Cancer Res 19 2013 1577 1586
20. I.I. Wistuba, C. Behrens, F. Lombardi, S. Wagner, J. Fujimoto, M.G. Raso, and et al. Validation of a proliferation-based expression signature as prognostic marker in early stage lung adenocarcinoma Clin Cancer Res 19 2013 6261 6271
21. J. Cuzick, D.M. Berney, G. Fisher, D. Mesher, H. Moller, J.E. Reid, and et al. Prognostic value of a cell cycle progression signature for prostate cancer death in a conservatively managed needle biopsy cohort Br J Cancer 106 2012 1095 1099
22. R. Bueno, E. Hughes, S. Wagner, A. Gutin, J.S. Lanchbury, Y. Zheng, and et al. Validation of a molecular and pathological model for five-year mortality risk in patients with early stage lung adenocarcinoma J Thorac Oncol 15 2015 67 73
23. L. McShane, D.G. Altman, W. Sauerbrei, S.E. Taube, M. Gion, and G.M. Clark Reporting recommendations for tumor marker prognostic studies J Clin Oncol 23 2005 9067 9072
24. G.M. Strauss, J.E. Herndon II, M.A. Maddaus, D.W. Johnstone, E.A. Johnson, D.H. Harpole, and et al. Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups J Clin Oncol 26 2008 5043 5051
25. J.J. Hung, W.J. Jeng, T.Y. Chou, W.H. Hsu, K.J. Wu, B.S. Huang, and et al. Prognostic value of the new International Association for the Study of Lung cancer/American Thoracic Society/European Respiratory Society lung adenocarcinoma classification on death and recurrence in completely resected stage I lung adenocarcinoma Ann Surg 258 2013 1079 1086
26. K. Kadota, J. Villena-Vargas, A. Yoshizawa, N. Motoi, C.S. Sima, G.J. Riely, and et al. Prognostic significance of adenocarcinoma in situ, and non-mucinous lepidic predominant invasive adenocarcinoma of the lung in patients with stage I disease Am J Surg Pathol 38 2014 448 460
27. K. Kadota, J. Nitadori, K.M. Woo, C.S. Sima, D.J. Finley, V.W. Rusch, and et al. Comprehensive pathological analyses in lung squamous cell carcinoma: single cell invasion, nuclear diameter and tumor budding are independent pathological factors for worse outcome J Thorac Oncol 9 2014 1126 1139
28. N.M. Mollberg, C. Bennette, E. Howell, L. Backhus, B. Devine, and M.K. Ferguson Lymphovascular invasion as a prognostic indicator in stage I non-small cell lung cancer: a systematic review and meta-analysis Ann Thorac Surg 97 2014 965 971
29. C. Desmedt, and C. Sotiriou Proliferation: the most prominent predictor of clinical outcome in breast cancer Cell Cycle 5 2006 2198 2202
30. J.N. Jacobsen, and J.B. Sorensen Clinical impact of ki-67 labeling index in non-small cell lung cancer Lung Cancer 79 2013 1 7
31. J.H. Von der Thuesen, Y.S. Tham, H. Pattenden, A. Rice, M. Dusmet, E. Lim, and et al. Prognostic significance of predominant histologic pattern and nuclear grade in resected adenocarcinoma of the lung: potential parameters for a grading system J Thorac Oncol 8 2013 37 44
32. K. Kadota, K. Suzuki, S.S. Kachala, E.C. Zabor, C.S. Sima, A.L. Moreira, and et al. A grading system combining architectural features and mitotic count predicts recurrence in stage I lung adenocarcinoma Mod Path 25 2012 1117 1127
33. P. Dubsky, M. Filipits, R. Jakesz, M. Rudas, C.F. Singer, R. Greil, and et al. EndoPredict improves the prognostic classification derived fromm common clinical guidelines in ER-positive, HER2-negative early breast cancer Ann Oncol 24 2013 640 647
34. M. Gnant, M. Filipits, R. Greil, H. Stoeger, M. Rudas, Z. Bago-Horvath, and et al. Predicting distant recurrence in receptor-positive breast cancer with limited clinicopathological risk: using the PAM50 Risk of Recurrence score in 1478 postmenopausal patients of the ABCSG-8 trial treated with adjuvant endocrine therapy alone Ann Oncol 25 2 2014 339 345